2021-04-14 · Press Release 14 April 2021 Immunicum AB E-mail: ir@immunicum.com. Investor Relations. Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400

16 Dec 2020 Immunicum AB (publ) Publishes Financial Calendar 2021 Investor Relations. Jonas Rodny and Carolin Wiken E-mail: ir@immunicum.com.

no. 556917-6596 LEI. 549300W31010S0FY9U64 Samtrygg Group AB - Org nr 556942-0911, Brahegatan 9 , SE-114 37 Stockholm +46 (0) 10 884 80 00 ir@samtrygg.se. Samtrygg Group AB. E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com INVESTOR RELATIONS. Jonas Rodny and Carolin Wiken Paues Åberg Communications Telephone: +46 190 90 51 E-mail: ir@immunicum.com Om Immunicum AB (publ) Immunicum etablerar ett unikt angreppssätt inom Pressmeddelande5 december 2017 Immunicum publicerar prospekt i samband med företrädesemission och notering på Nasdaq StockholmImmunicum AB (publ) ("Immunicum" eller "Bolaget"), First North Premier: (IMMU), ett bioteknikbolag som utvecklar nya im 2021-04-07 · Immunicum AB (publ) today announced its participation in multiple upcoming investor conferences in April and that it will host a virtual Investor Event on Thursday, April 22, 2021. Immunicum AB (publ) meddelar att Lotta Ferm har utsetts till ny tillförordnad finanschef.

Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com. Press Release 7 April 2021 Immunicum Announces Investor Event and Conference Participation for April Immunicum AB (publ) today announced its participation in multiple upcoming investor conferences in April and that it will host a virtual Investor Event on Thursday, April 22, 2021. The event will feature presentations by Immunicum’s management team to provide an overview of the Company’s Investor & Public Relations Manager +46 (0)735 414573. Vacancies.

Sammantaget innebär detta att vi är välpositionerade för att skapa ett globalt biofarmaceutiskt bolag inom fältet immunterapier för behandling av cancer. Immunicum AB anlitar ny Investor Relations firma Göteborg, 14 mars 2016 - Immunicum AB (publ), som strävar efter att utveckla avancerade, säkra och effektiva terapeutiska cancerbehandlingar med kraftfulla och långvariga immunsvar, meddelade idag att Bolaget har anlitat The Blueshirt Group för att bistå Immunicum i att utveckla sin kommunikation och kontakter med den globala finansvärlden. Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai Immunicum Investor Event on April 22, 2021 at 1:00 pm CET Press Release.

Pressmeddelande5 december 2017 Immunicum publicerar prospekt i samband med företrädesemission och notering på Nasdaq StockholmImmunicum AB (publ) ("Immunicum" eller "Bolaget"), First North Premier: (IMMU), ett bioteknikbolag som utvecklar nya im

Investor Relations. Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders in convenient administration forms. 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com.

Köp aktier i Immunicum - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

// Investor Relations Game Chest Group AB(publ) ir@gamechestgroup.se Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events. Immunicum AB (publ) Announces Upcoming Virtual Investor Event on December 9 th. Immunicum AB (publ; IMMU.ST) announced today that the Company will host a virtual Investor Event on Wednesday, December 9 th at 15:00 CET. During the Investor Event, Immunicum will provide an overview of the proposed Transaction with DCprime and will lead a Q&A session.

2016-03-14 2021-04-14 Immunicum AB / Tur att jag inte skrev något i morse om att kursen borde vända uppåt idag / Tur att jag inte skrev något i morse om att kursen borde vända uppåt svara mig själv. Han är tydligen numera Head of Investor Relations & Corporate Communication. Passar väl bra, vill minnas att han är holländare. Redigerades igår 16:35. 2021-04-12 Press Release 1 December 2020 Immunicum AB (publ) Announces Upcoming Virtual Investor Event on December 9th Immunicum AB (publ; IMMU.ST) announced today that the Company will host a virtual Investor Event on Wednesday, December 9th at 15:00 CET. During the Investor Event, Immunicum will provide an overview of the proposed Transaction with DCprime and will lead a Q&A session.
Tim anställning jobb

Investor Relations.
Visit värnamo turistinformation

Telephone: +49 171 351 2733. E-mail: ir@immunicum.com. ABOUT IMMUNICUM AB (PUBL). Immunicum is establishing a unique immuno-oncology approach

Immunicum AB (publ; IMMU.ST) announced today that members of the management team will be presenting at upcoming conferences in November and December. Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event Summary. Immunicum AB (publ; IMMU.ST) provided today an overview and details on the topics to be covered during the previously announced Investor Event regarding the proposed combination between Immunicum and DCprime. Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events. 2016-03-14 · Julie Silber, Investor Relations ir@immunicum.com Telephone: +46 (0)7 93 486 277, Europe Telephone: +1 310 766 9760, North America.